Skip to main content

Table 1 Background data of the population

From: Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF)

 

Treatment group (n = 57)

Control group (n = 57)

Age (years old)

 Mean

69.0

71.6

 Standard deviation

11.6

10.8

Gender

 Male

45 (79%)

41 (72%)

 Female

12 (21%)

16 (28%)

First treatment

 Yes

49 (86%)

53 (93%)

 No

8 (14%)

4 (7%)

Type of amputation

 Digital

49 (86%)

49 (86%)

 Transmetatarsal

8 (14%)

8 (14%)

Related pathologies

53 (93%)

57 (100%)

 Hypertension

50 (88%)

50 (88%)

 Chronic renal failure

20 (35%)

28 (49%)

 Hemodialysis

6 (10%)

1 (2%)

 Heart diseases

35 (61%)

43 (75%)

 Neurological disorders

2 (4%)

8 (14%)

 Autoimmune disorders

1 (2%)

 Chronic respiratory failure

9 (16%)

14 (25%)

 Others

9 (16%)

10 (18%)

Smoke

 Yes

11 (20%)

8 (14%)

 Former

23 (40%)

24 (42%)

 No

23 (40%)

25 (44%)

Concomitant therapies

57 (100%)

57 (100%)

 Oral anticoagulant

8 (14%)

15 (26%)

 Antiplatelet

53 (93%)

53 (93%)

 Insulin

37 (65%)

46 (81%)

 OHAs

32 (56%)

25 (44%)

 NSAIDs

8 (14%)

9 (16%)

 Opioid

6 (10%)

7 (12%)

 Antibiotics

10 (18%)

6 (10%)

 Others

7 (12%)

3 (5%)

  1. Continuous data are presented as means and standard deviation. Categorical data are given as counts (%)
  2. OHAs oral hypoglycemic agents, NSAIDs non-steroidal anti-inflammatory drugs